Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | ACP1 | P24666 | 2/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946874 | 0.81 | PTPN1 (0.42) | ALDH1A1CYP2C9PTPN1ACP1CDC25B | |
| SCHEMBL10988669 | 0.77 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP2C9LMNAPTPN1 | |
| SCHEMBL7137074 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2LMNAPTPN1CRHBP | |
| SCHEMBL3082564 | 0.71 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP2C9LMNAPTPN1 | |
| SCHEMBL10990467 | 0.71 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP2C9LMNACRHBP | |
| SCHEMBL4928133 | 0.69 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2L3MBTL1KDM4ETSHR | |
| SCHEMBL2062684 | 0.68 | ALDH1A1 (0.44) | ALDH1A1CYP2C9PTPN1ACP1CDC25B | |
| SCHEMBL9730908 | 0.68 | — | — | |
| SCHEMBL12041925 | 0.67 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CYP2C9LMNAPTPN1 | |
| SCHEMBL5171537 | 0.66 | PTPN1 (0.45) | ALDH1A1SMN1; SMN2CYP2C9LMNAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4547516-A | Antisecretory agents derived from meldrum's acid | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-10-15 | — | — | US | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20060270671-A1 | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| US-20060264623-A1 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| US-7119102-B2 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050182053-A1 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-20030105073-A1 | Quinolone derivatives | CELLTECH R&D LIMITED (GB) | 2003-06-05 | — | — | US | disclosed |
| WO-2003035066-A1 | 2-AMINOQUINOLONE DERIVATIVES FOR USE AS IMPDH INHIBITORS | CELLTECH R & D LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885SMN1; SMN2 4421/4885CYP2C9 2733/4885 |
| US-20050182053-A1 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKG, IKBKE | ALDH1A1 3655/4885SMN1; SMN2 3793/4885CYP2C9 1657/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885SMN1; SMN2 4421/4885CYP2C9 2733/4885 |
| US-20060270671-A1 | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | CPS1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TK2 | ALDH1A1 371/4885SMN1; SMN2 1808/4885CYP2C9 117/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885SMN1; SMN2 4421/4885CYP2C9 2733/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885SMN1; SMN2 4421/4885CYP2C9 2733/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ALDH1A1 2072/4885SMN1; SMN2 4421/4885CYP2C9 2733/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ALDH1A1 2578/4885SMN1; SMN2 4701/4885CYP2C9 3367/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885SMN1; SMN2 4701/4885CYP2C9 3367/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ALDH1A1 2578/4885SMN1; SMN2 4701/4885CYP2C9 3367/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885SMN1; SMN2 4421/4885CYP2C9 2733/4885 |
| US-20060264623-A1 | DNA-PK inhibitors | TOP2B, TOP2A, POLN | ALDH1A1 2579/4885SMN1; SMN2 4103/4885CYP2C9 709/4885 |
| US-20030105073-A1 | Quinolone derivatives | IFNAR1, CBR1, IMPDH1 | ALDH1A1 345/4885SMN1; SMN2 4781/4885CYP2C9 178/4885 |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | POLK, DCK, POLN | ALDH1A1 1666/4885SMN1; SMN2 2812/4885CYP2C9 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.